Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miso Kim

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
ESMO Open|December 6, 2019
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysisChanghee Park, Bhumsuk Keam, Soon Ho Yoon, et al.
Journal of Thoracic Disease|August 14, 2025
Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinomaDong Hyun Kim, Yoojoo Lim, Sanghoon Song, et al.
Thoracic Cancer|September 7, 2023
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort studyDong Hyun Kim, Yoojoo Lim, Sukjun Kim, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissuesShin Hye Yoo, Jihui Yun, Bhumsuk Keam, et al.
Thoracic Cancer|January 18, 2021
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancerEun Hee Jung, Hee Ryeong Jang, Se Hyun Kim, et al.
Cancer Medicine|June 2, 2023
Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06Byeong Seok Sohn, Jeongeun Kim, Miso Kim, et al.
Cancer Research and Treatment|August 5, 2016
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal CancerMiso Kim, Bhumsuk Keam, Tae-Min Kim, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2013
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancerJin Won Kim, Hyun Jin Cho, Miso Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2024
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancerSiyeon Park, Seongyeol Park, Tae Min Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|January 13, 2026
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trialsDong Hyun Kim, Miso Kim, Jeonghwan Youk, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
ESMO Open|December 6, 2019
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysisChanghee Park, Bhumsuk Keam, Soon Ho Yoon, et al.
Journal of Thoracic Disease|August 14, 2025
Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinomaDong Hyun Kim, Yoojoo Lim, Sanghoon Song, et al.
Thoracic Cancer|September 7, 2023
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort studyDong Hyun Kim, Yoojoo Lim, Sukjun Kim, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissuesShin Hye Yoo, Jihui Yun, Bhumsuk Keam, et al.
Thoracic Cancer|January 18, 2021
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancerEun Hee Jung, Hee Ryeong Jang, Se Hyun Kim, et al.
Cancer Medicine|June 2, 2023
Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06Byeong Seok Sohn, Jeongeun Kim, Miso Kim, et al.
Cancer Research and Treatment|August 5, 2016
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal CancerMiso Kim, Bhumsuk Keam, Tae-Min Kim, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2013
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancerJin Won Kim, Hyun Jin Cho, Miso Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2024
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancerSiyeon Park, Seongyeol Park, Tae Min Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|January 13, 2026
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trialsDong Hyun Kim, Miso Kim, Jeonghwan Youk, et al.
Pageof 19